Conclusion
For patients with BRCA1/2-mutated ovarian cancer with secondary platinum-sensitive recurrence, the therapeutic effect of PARPi monotherapy and platinum-based chemotherapy was equivalent. PARPi monotherapy does not negatively affect the efficacy of subsequent platinum-based chemotherapy after the progression of PARPi monotherapy and could improve prognosis.